Immunetune Appoints Paul van der Horst and Johan Devenyns to its Supervisory Board

Jan 25, 2022

Immunetune Appoints Paul van der Horst and Johan Devenyns to its Supervisory Board

LEIDEN, the Netherlands, January 25, 2022 — Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced the appointment of Paul van der Horst and Johan Devenyns as independent members in the Supervisory Board.

“We are excited to strengthen our board with the appointment of two additional members, who have proven themselves in the biotech industry in terms of M&A, fundraising and development strategy. These areas of expertise will be crucial as we enter our next phase of clinical development and pursue the financing to execute our strategy,” said Ron Verweij, chairman of the Supervisory Board of Immunetune. 

Dr. Paul van der Horst is Chief Business Officer at Agomab Therapeutics, Belgium. Prior to Agomab, he was Head of Corporate Development at Galapagos NV (NASDAQ: GLPG) from 2016-2021, during which he led all major transactions, investments, licensing, and M&A activities. From 2013-2016, he worked at boutique investment bank Kempen & Co in Amsterdam, where he was responsible for broking and dealing of European pharma & biotech stocks to institutional investors in Europe and the US. Paul has been the lead negotiator and deal lead in over 20 pharmaceutical licensing and M&A transactions and has raised over USD1.3bn through equity capital market transactions. Paul is a member of the Board of Directors at OncoArendi (Warsaw, Poland) and holds a PhD in Gynecological Oncology from the Erasmus University Medical Centre in Rotterdam, the Netherlands.

“I am impressed by Immunetune’s preclinical data and the differentiation of their next-generation vaccines, especially the wealth of in vivo data supporting the neoantigen cancer vaccine and its novel adjuvant to prime a specific anti-tumor immune response. I am looking forward to share my experience in business and corporate development to propel these programs further,” stated Paul van der Horst.

Dr. Johan Devenyns is a certified director and former CEO of PharmaFluidics, recently acquired by life sciences giant Thermo Fisher Scientific. Prior assignments include management, consolidation and trade sale of Solvay’s peptide, nucleotide CDMO businesses in Belgium, Germany and the US. He has served as a board member of BIO.be, Belgium’s Life Sciences sector federation and has an extensive contact network in the biopharma and venture capital industries.

“It is great to join a growing biotech and inspiring team that is poised to make great impact with its novel vaccine technology platform for treating cancer patients. I intend to share my experience in governance, funding and alliance development to build such an innovative company,” added Johan Devenyns.

About Immunetune

Immunetune is a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases. Its proprietary set of technologies allow the rapid, cell-free production of personalized cancer vaccines encoding multiple (neo-)antigens in synthetic, linear DNA with improved immunogenicity through its unique PyroVant™ adjuvant. Its lead cancer vaccine has achieved preclinical Proof of Concept in animal studies and is finalizing its preclinical package with the aim to initiate clinical studies in 2022. Immunetune’s pipeline further consists of infectious disease vaccines, including a pan-corona DNA vaccine, targeting antigens conserved across multiple strains of coronaviruses for global pandemic readiness, currently in preclinical testing.

www.immunetune.com

For more information, please contact:

Sijme Zeilemaker
Chief Executive Officer
Telephone: +31 71 3322 388
E-mail: info@immunetune.com